IDR Data
CMS PUF data · 2023 Q1–2025 Q4

Federal IDR outcomes: General and other surgery in Texas

In 2025 Q1–Q4, the provider or facility offer prevailed in 78.6% of 4,064 determined Federal IDR dispute line items for general and other surgery in Texas. The median prevailing offer was 9.35x the QPA (25th–75th percentile 3.30x–24.25x; n = 2,545). The median time to a decision was 31 business days (n = 4,064).

Determined line items

4,064

2025 Q1–Q4 · 0 split decisions excluded

Provider win rate

78.6%

n = 4,064 · 2025 Q1–Q4

Median payment vs QPA

9.35x

middle half 3.30x–24.25x · n = 2,545 · 2025 Q1–Q4

Median days to decision

31

business days, from dispute initiation · n = 4,064 · 2025 Q1–Q4

Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.

By period

PeriodLine itemsWin %Median ×QPA25th–75thRatio nMedian days
2025 Q1–Q44,06478.6%9.35x3.30x–24.25x2,54531
2024 Q1–Q467189.0%4.48x1.10x–10.98x37541
2023 Q1–Q412335.8%0.80x0.17x–1.00x11899
2023 Q1–2025 Q44,85879.0%7.30x2.43x–20.74x3,038not pooled

Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.

Most disputed CPT codes

CPT codeLine itemsWin %Median ×QPARatio nMedian days
99285 Emergency department visit with high level of medical decision making12387.8%6.20x6033
22558 Fusion of lower spine bone through abdomen with partial removal of disc11190.1%16.63x4028
44970 Removal of appendix using an endoscope10385.4%19.31x4629
85025 Complete blood cell count (red cells, white blood cell, platelets), automated te9175.8%9.87x5431
80051 Blood test panel for electrolytes (sodium potassium, chloride, carbon dioxide)8375.9%9.87x5131
82550 Creatine kinase (cardiac enzyme) level, total8375.9%9.87x5131
82565 Blood creatinine level8375.9%9.87x5131
84520 Urea nitrogen level to assess kidney function, quantitative8375.9%9.87x5131
82947 Blood glucose (sugar) level8276.8%9.87x5031.5
99291 Critical care, first 30-74 minutes7693.4%3.36x5932
96361 Infusion into a vein for hydration, each additional hour6877.9%9.87x4032.5
47562 Removal of gallbladder using an endoscope6587.7%–2829
84155 Total protein level, blood6071.7%7.30x3532.5
22585 Fusion of spine bones through front of body with partial removal of disc, each a5989.8%–1930
82040 Albumin (protein) level5870.7%7.29x3533
82150 Amylase (enzyme) level5870.7%7.29x3533
82247 Bilirubin level, total5870.7%7.29x3533
82977 Glutamyltransferase (liver enzyme) level5870.7%7.29x3533
84075 Phosphatase (enzyme) level, alkaline5870.7%7.29x3533
84450 Liver enzyme (SGOT), level5870.7%7.29x3533

2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.

Related: all specialties in Texas · General and other surgery in all states

FAQ

What is the Federal IDR provider win rate for general and other surgery in Texas?

In 2025 Q1–Q4, the provider or facility offer was selected in 78.6% of 4,064 determined dispute line items for general and other surgery in Texas. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.

How do Federal IDR payments compare with the QPA for general and other surgery in Texas?

In 2025 Q1–Q4, the median prevailing offer was 9.35x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 3.30x to 24.25x (n = 2,545 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.

How long do Federal IDR decisions take for general and other surgery in Texas?

In 2025 Q1–Q4, the median was 31 business days (n = 4,064 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).

How to Utilize IDR